Geratherm Medical AG Logo

Geratherm Medical AG

GME.DE

(2.0)
Stock Price

3,40 EUR

2.44% ROA

3.37% ROE

26.38x PER

Market Cap.

20.132.443,00 EUR

46.87% DER

2.69% Yield

4.83% NPM

Geratherm Medical AG Stock Analysis

Geratherm Medical AG Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Geratherm Medical AG Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (36%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Dividend

The company's consistent dividend distribution over the past five years reflects its dedication to providing shareholders with steady returns, making it an appealing choice for investors seeking income stability.

3 ROE

The stock's ROE falls within an average range (2.45%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (1.21%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

5 PBV

The stock's PBV ratio (1.36x) indicates a justifiable valuation, presenting a compelling choice for investors seeking reasonable returns.

6 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (510) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

9 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

10 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

11 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

Geratherm Medical AG Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Geratherm Medical AG Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Geratherm Medical AG Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Geratherm Medical AG Revenue
Year Revenue Growth
2002 7.246.408
2003 7.757.999 6.59%
2004 7.735.128 -0.3%
2005 8.459.672 8.56%
2006 8.589.613 1.51%
2007 8.802.003 2.41%
2008 10.734.564 18%
2009 14.914.436 28.03%
2010 17.783.097 16.13%
2011 18.981.111 6.31%
2012 16.280.276 -16.59%
2013 17.029.040 4.4%
2014 18.714.641 9.01%
2015 21.588.895 13.31%
2016 22.062.984 2.15%
2017 21.030.779 -4.91%
2018 21.521.920 2.28%
2019 19.851.176 -8.42%
2020 27.466.230 27.73%
2021 24.638.673 -11.48%
2022 25.850.619 4.69%
2023 19.552.144 -32.21%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Geratherm Medical AG Research and Development Expenses
Year Research and Development Expenses Growth
2002 0
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 469.433 100%
2013 499.053 5.94%
2014 402.999 -23.83%
2015 409.168 1.51%
2016 489.393 16.39%
2017 619.000 20.94%
2018 1.081.000 42.74%
2019 1.399.000 22.73%
2020 1.753.000 20.19%
2021 1.370.000 -27.96%
2022 1.281.000 -6.95%
2023 1.358.000 5.67%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Geratherm Medical AG General and Administrative Expenses
Year General and Administrative Expenses Growth
2002 1.669.828
2003 1.763.534 5.31%
2004 1.938.859 9.04%
2005 2.069.973 6.33%
2006 0 0%
2007 0 0%
2008 2.105.836 100%
2009 0 0%
2010 3.230.401 100%
2011 0 0%
2012 1.900.000 100%
2013 1.459.000 -30.23%
2014 2.288.000 36.23%
2015 2.392.000 4.35%
2016 2.667.000 10.31%
2017 2.482.000 -7.45%
2018 2.885.000 13.97%
2019 2.479.000 -16.38%
2020 2.850.000 13.02%
2021 3.437.000 17.08%
2022 3.276.000 -4.91%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Geratherm Medical AG EBITDA
Year EBITDA Growth
2002 1.808.588
2003 2.094.818 13.66%
2004 1.920.611 -9.07%
2005 1.994.048 3.68%
2006 5.660.308 64.77%
2007 5.856.841 3.36%
2008 977.900 -498.92%
2009 1.951.184 49.88%
2010 4.021.785 51.48%
2011 2.604.649 -54.41%
2012 1.836.143 -41.85%
2013 1.469.305 -24.97%
2014 3.130.987 53.07%
2015 3.302.984 5.21%
2016 3.651.201 9.54%
2017 2.138.073 -70.77%
2018 2.849.041 24.95%
2019 2.373.689 -20.03%
2020 4.242.624 44.05%
2021 2.301.600 -84.33%
2022 2.863.060 19.61%
2023 4.040.032 29.13%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Geratherm Medical AG Gross Profit
Year Gross Profit Growth
2002 4.213.671
2003 4.560.966 7.61%
2004 4.701.162 2.98%
2005 4.814.098 2.35%
2006 4.494.308 -7.12%
2007 4.628.841 2.91%
2008 6.093.746 24.04%
2009 8.712.419 30.06%
2010 10.615.528 17.93%
2011 11.040.518 3.85%
2012 9.104.355 -21.27%
2013 8.750.222 -4.05%
2014 11.055.055 20.85%
2015 13.343.446 17.15%
2016 14.630.744 8.8%
2017 13.268.456 -10.27%
2018 14.208.061 6.61%
2019 13.682.436 -3.84%
2020 17.596.364 22.24%
2021 16.320.775 -7.82%
2022 6.380.772 -155.78%
2023 15.684.880 59.32%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Geratherm Medical AG Net Profit
Year Net Profit Growth
2002 952.138
2003 1.558.097 38.89%
2004 1.332.705 -16.91%
2005 1.426.919 6.6%
2006 0 0%
2007 0 0%
2008 -2.920.617 100%
2009 2.678.545 209.04%
2010 2.542.290 -5.36%
2011 1.095.115 -132.15%
2012 1.194.190 8.3%
2013 1.333.781 10.47%
2014 1.682.359 20.72%
2015 2.701.265 37.72%
2016 2.236.805 -20.76%
2017 679.787 -229.04%
2018 1.153.595 41.07%
2019 289.857 -297.99%
2020 2.045.328 85.83%
2021 332.647 -514.86%
2022 1.023.446 67.5%
2023 811.440 -26.13%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Geratherm Medical AG Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2002 0
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 -1 0%
2009 1 0%
2010 1 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 1 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Geratherm Medical AG Free Cashflow
Year Free Cashflow Growth
2002 7.000
2003 1.520.000 99.54%
2004 720.000 -111.11%
2005 654.000 -10.09%
2006 240.920 -171.46%
2007 1.038.620 76.8%
2008 -251.000 513.79%
2009 1.881.000 113.34%
2010 -808.000 332.8%
2011 128.000 731.25%
2012 789.000 83.78%
2013 1.897.000 58.41%
2014 455.000 -316.92%
2015 2.993.000 84.8%
2016 -256.000 1269.14%
2017 964.000 126.56%
2018 -3.801.000 125.36%
2019 -1.412.000 -169.19%
2020 1.136.000 224.3%
2021 -353.000 421.81%
2022 -133.000 -165.41%
2023 -232.500 42.8%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Geratherm Medical AG Operating Cashflow
Year Operating Cashflow Growth
2002 203.000
2003 1.688.000 87.97%
2004 871.000 -93.8%
2005 860.000 -1.28%
2006 240.920 -256.96%
2007 1.038.620 76.8%
2008 473.000 -119.58%
2009 2.710.000 82.55%
2010 427.000 -534.66%
2011 1.063.000 59.83%
2012 1.605.000 33.77%
2013 2.438.000 34.17%
2014 952.000 -156.09%
2015 3.774.000 74.77%
2016 792.000 -376.52%
2017 2.466.000 67.88%
2018 1.347.000 -83.07%
2019 1.540.000 12.53%
2020 3.915.000 60.66%
2021 917.000 -326.94%
2022 2.606.000 64.81%
2023 48.500 -5273.2%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Geratherm Medical AG Capital Expenditure
Year Capital Expenditure Growth
2002 196.000
2003 168.000 -16.67%
2004 151.000 -11.26%
2005 206.000 26.7%
2006 0 0%
2007 0 0%
2008 724.000 100%
2009 829.000 12.67%
2010 1.235.000 32.87%
2011 935.000 -32.09%
2012 816.000 -14.58%
2013 541.000 -50.83%
2014 497.000 -8.85%
2015 781.000 36.36%
2016 1.048.000 25.48%
2017 1.502.000 30.23%
2018 5.148.000 70.82%
2019 2.952.000 -74.39%
2020 2.779.000 -6.23%
2021 1.270.000 -118.82%
2022 2.739.000 53.63%
2023 281.000 -874.73%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Geratherm Medical AG Equity
Year Equity Growth
2002 15.680.135
2003 16.470.467 4.8%
2004 16.741.617 1.62%
2005 17.122.288 2.22%
2006 17.448.000 1.87%
2007 16.254.000 -7.35%
2008 12.647.078 -28.52%
2009 17.670.426 28.43%
2010 20.516.756 13.87%
2011 18.664.885 -9.92%
2012 18.621.275 -0.23%
2013 20.080.391 7.27%
2014 20.342.958 1.29%
2015 21.939.217 7.28%
2016 20.556.902 -6.72%
2017 21.017.053 2.19%
2018 20.127.652 -4.42%
2019 19.180.782 -4.94%
2020 19.925.458 3.74%
2021 18.631.356 -6.95%
2022 22.227.913 16.18%
2023 22.611.068 1.69%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Geratherm Medical AG Assets
Year Assets Growth
2002 18.899.248
2003 19.139.513 1.26%
2004 18.874.115 -1.41%
2005 18.553.641 -1.73%
2006 19.019.930 2.45%
2007 18.166.340 -4.7%
2008 15.060.447 -20.62%
2009 22.652.160 33.51%
2010 29.961.424 24.4%
2011 24.583.038 -21.88%
2012 27.384.848 10.23%
2013 28.697.465 4.57%
2014 28.489.393 -0.73%
2015 30.248.015 5.81%
2016 28.402.637 -6.5%
2017 28.466.701 0.23%
2018 29.380.254 3.11%
2019 33.264.443 11.68%
2020 35.990.460 7.57%
2021 34.560.415 -4.14%
2022 38.380.396 9.95%
2023 35.719.206 -7.45%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Geratherm Medical AG Liabilities
Year Liabilities Growth
2002 3.211.263
2003 2.667.989 -20.36%
2004 2.101.394 -26.96%
2005 1.431.353 -46.81%
2006 1.571.930 8.94%
2007 1.912.340 17.8%
2008 2.413.369 20.76%
2009 4.981.734 51.56%
2010 9.444.668 47.25%
2011 5.918.153 -59.59%
2012 8.763.573 32.47%
2013 8.617.074 -1.7%
2014 8.146.435 -5.78%
2015 8.308.798 1.95%
2016 7.845.735 -5.9%
2017 7.449.648 -5.32%
2018 9.252.602 19.49%
2019 14.083.661 34.3%
2020 16.065.002 12.33%
2021 15.929.059 -0.85%
2022 14.637.209 -8.83%
2023 13.108.138 -11.67%

Geratherm Medical AG Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2.92
Net Income per Share
0.14
Price to Earning Ratio
26.38x
Price To Sales Ratio
1.28x
POCF Ratio
25.51
PFCF Ratio
161.71
Price to Book Ratio
0.9
EV to Sales
1.41
EV Over EBITDA
7.42
EV to Operating CashFlow
28.2
EV to FreeCashFlow
177.71
Earnings Yield
0.04
FreeCashFlow Yield
0.01
Market Cap
0,02 Bil.
Enterprise Value
0,02 Bil.
Graham Number
3.63
Graham NetNet
0.14

Income Statement Metrics

Net Income per Share
0.14
Income Quality
1.03
ROE
0.03
Return On Assets
0.02
Return On Capital Employed
0.05
Net Income per EBT
0.53
EBT Per Ebit
0.88
Ebit per Revenue
0.1
Effective Tax Rate
0.29

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.04
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.78
Operating Profit Margin
0.1
Pretax Profit Margin
0.09
Net Profit Margin
0.05

Dividends

Dividend Yield
0.03
Dividend Yield %
2.69
Payout Ratio
1.07
Dividend Per Share
0.1

Operating Metrics

Operating Cashflow per Share
0.15
Free CashFlow per Share
0.02
Capex to Operating CashFlow
0.84
Capex to Revenue
0.04
Capex to Depreciation
0.49
Return on Invested Capital
0.04
Return on Tangible Assets
0.02
Days Sales Outstanding
44.32
Days Payables Outstanding
87.84
Days of Inventory on Hand
973.89
Receivables Turnover
8.24
Payables Turnover
4.16
Inventory Turnover
0.37
Capex per Share
0.12

Balance Sheet

Cash per Share
1,44
Book Value per Share
4,20
Tangible Book Value per Share
3.34
Shareholders Equity per Share
4.15
Interest Debt per Share
1.95
Debt to Equity
0.47
Debt to Assets
0.29
Net Debt to EBITDA
0.67
Current Ratio
14.23
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
33616699
Working Capital
0,02 Bil.
Intangibles to Total Assets
0.13
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
9373697
Debt to Market Cap
0.52

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Geratherm Medical AG Dividends
Year Dividends Growth
2003 0
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 1 0%
2017 1 0%
2018 0 0%
2019 0 0%
2020 1 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

Geratherm Medical AG Profile

About Geratherm Medical AG

Geratherm Medical AG operates as a medical technology company in Germany. It operates through Healthcare Diagnostic, Respiratory, Cardio/Stroke, and Medical Warming Systems segments. The Healthcare Diagnostic segment provides clinical thermometers; blood pressure monitors; and self-test diagnostic products for women, including pregnancy tests, chlamydia tests, urinary tract infections, diverse ovulation test solutions, and pH tests. The Respiratory segment develops and manufactures products primarily for pulmonary and cardiopulmonary function diagnostics. The Medical Warming Systems segment offers MRI-compatible incubators for premature and newborn infants under the LMT brand. The Cardio/Stroke segment offers stroke risk analysis products for the detection of atrial fibrillation. The company markets its products through pharmacies, hospitals, and clinics. It exports its products to approximately 60 countries. The company was founded in 1990 and is headquartered in Geschwenda, Germany.

CEO
Mr. Christian Frick
Employee
179
Address
Fahrenheitstrasse 1
Geschwenda, 99331

Geratherm Medical AG Executives & BODs

Geratherm Medical AG Executives & BODs
# Name Age
1 Mr. Christian Frick
Chief Executive Officer & Member of Management Board
70

Geratherm Medical AG Competitors